AI Uncovers Hidden Cell Surface Drug Targets Missed by Major Databases

More than 65% of approved drugs act on proteins on the surface of human cells, but researchers face a major hurdle: key biological databases often disagree about which proteins are actually present on cell surfaces. This inconsistency can stall drug discovery and lead to missed therapeutic opportunities. A new artificial intelligence system has been developed to systematically flag potential cell surface proteins that major databases have overlooked. By analyzing vast amounts of biological data, the AI identifies proteins likely to be on the cell surface, even when existing resources fail to list them. This approach could help scientists prioritize new drug targets for cancer, autoimmune diseases, and other conditions. The work highlights the power of machine learning to resolve long-standing data conflicts in biology. With more reliable surface protein maps, researchers can accelerate the development of next-generation medicines. The next step is to validate these AI-flagged targets in the lab and integrate the findings into public databases for broader use.